Status:
UNKNOWN
Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer is a major cause of survival for women worldwide. Neoadjuvant therapy as an important treatment for locally advanced breast cancer has had many positive effects for breast cancer patient...
Detailed Description
Breast cancer is the most prevalent cancer among women worldwide. Neoadjuvant treatment (NAT) is part of the standardized treatment of breast cancer and is especially important for locally advanced br...
Eligibility Criteria
Inclusion
- patients admitted to each study center between January 1, 2010 and December 31, 2021.
- ≥18 years of age, female, with an ECOG score ≤2.
- pathological biopsy confirmed invasive breast cancer.
- were initially treated with neoadjuvant therapy.
- have MRI imaging data prior to radical surgery after neoadjuvant treatment.
- underwent surgery as planned after neoadjuvant therapy and obtained postoperative pathology information.
Exclusion
- Bilateral breast cancer, multiple lesions or occult breast cancer.
- no data related to breast MRI.
- no surgery after neoadjuvant therapy, no postoperative pathology results.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
1821 Patients enrolled
Trial Details
Trial ID
NCT05441098
Start Date
April 1 2022
End Date
December 31 2022
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021